Newron Pharmaceuticals SpA Asset Resilience Ratio

Latest as of December 2025: 41.67%

Newron Pharmaceuticals SpA asset resilience ratio. Newron Pharmaceuticals SpA (NWRN) has an Asset Resilience Ratio of 41.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Newron Pharmaceuticals SpA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CHF16.68 Million
≈ $21.08 Million USD Cash + Short-term Investments

Total Assets

CHF40.02 Million
≈ $50.60 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Newron Pharmaceuticals SpA (2009–2025)

Asset resilience ratio of Newron Pharmaceuticals SpA from 2009 to 2025. This chart shows how Newron Pharmaceuticals SpA's Asset Resilience Ratio has changed over time. Read total liabilities of Newron Pharmaceuticals SpA for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Newron Pharmaceuticals SpA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Newron Pharmaceuticals SpA (NWRN) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF0.00 0%
Short-term Investments CHF16.68 Million 41.67%
Total Liquid Assets CHF16.68 Million 41.67%

Asset Resilience Insights

  • Very High Liquidity: Newron Pharmaceuticals SpA maintains exceptional liquid asset reserves at 41.67% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Newron Pharmaceuticals SpA Industry Peers by Asset Resilience Ratio

Compare Newron Pharmaceuticals SpA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Newron Pharmaceuticals SpA Asset Resilience Ratio by Year (2009–2025)

Newron Pharmaceuticals SpA asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Newron Pharmaceuticals SpA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 41.67% CHF16.68 Million
≈ $21.08 Million
CHF40.02 Million
≈ $50.60 Million
+37.14pp
2024-12-31 4.53% CHF2.89 Million
≈ $3.66 Million
CHF63.91 Million
≈ $80.80 Million
-19.68pp
2023-12-31 24.21% CHF6.26 Million
≈ $7.92 Million
CHF25.87 Million
≈ $32.70 Million
-0.93pp
2022-12-31 25.14% CHF9.35 Million
≈ $11.82 Million
CHF37.20 Million
≈ $47.02 Million
+6.17pp
2021-12-31 18.97% CHF9.57 Million
≈ $12.11 Million
CHF50.49 Million
≈ $63.83 Million
-16.26pp
2020-12-31 35.23% CHF18.04 Million
≈ $22.80 Million
CHF51.20 Million
≈ $64.73 Million
+6.85pp
2019-12-31 28.38% CHF17.11 Million
≈ $21.63 Million
CHF60.29 Million
≈ $76.22 Million
+1.33pp
2018-12-31 27.05% CHF16.23 Million
≈ $20.52 Million
CHF60.00 Million
≈ $75.85 Million
+0.43pp
2017-12-31 26.62% CHF19.44 Million
≈ $24.58 Million
CHF73.02 Million
≈ $92.32 Million
+20.40pp
2016-12-31 6.22% CHF3.52 Million
≈ $4.45 Million
CHF56.59 Million
≈ $71.55 Million
-4.87pp
2015-12-31 11.09% CHF4.92 Million
≈ $6.22 Million
CHF44.38 Million
≈ $56.11 Million
-7.65pp
2014-12-31 18.74% CHF6.95 Million
≈ $8.78 Million
CHF37.07 Million
≈ $46.87 Million
+1.48pp
2013-12-31 17.26% CHF5.46 Million
≈ $6.90 Million
CHF31.62 Million
≈ $39.97 Million
+9.10pp
2012-12-31 8.16% CHF3.64 Million
≈ $4.60 Million
CHF44.65 Million
≈ $56.45 Million
+4.30pp
2009-12-31 3.85% CHF1.60 Million
≈ $2.03 Million
CHF41.68 Million
≈ $52.69 Million
--
pp = percentage points

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology
Market Cap
$232.53 Million
CHF183.92 Million CHF
Market Cap Rank
#15779 Global
#170 in Switzerland
Share Price
CHF8.84
Change (1 day)
-1.78%
52-Week Range
CHF7.21 - CHF30.40
All Time High
CHF30.40
About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more